Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969167 | 0.82 | CYP2A6 (0.51) | CYP2A6SLC22A12TRPV1CNR2 | |
| SCHEMBL10094707 | 0.81 | CLK4 (0.60) | CYP2A6TDO2 | |
| SCHEMBL2477267 | 0.79 | TRPV1 (0.62) | CYP2A6TRPV1CNR2ALDH1A1 | |
| SCHEMBL9988420 | 0.79 | SLC22A12 (0.48) | SLC22A12CYP11B2TDO2TRPV1EGLN2 | |
| SCHEMBL28415529 | 0.79 | SLC22A12 (0.48) | SLC22A12CYP11B2TDO2TRPV1CNR2 | |
| SCHEMBL2142400 | 0.79 | KDM4E (0.56) | SLC22A12CYP11B2TDO2TRPV1ALDH1A1 | |
| SCHEMBL9987695 | 0.79 | SLC22A12 (0.48) | SLC22A12CYP11B2TDO2TRPV1 | |
| SCHEMBL10061101 | 0.79 | SLC22A12 (0.48) | SLC22A12CYP11B2TDO2TRPV1SMO | |
| SCHEMBL22628964 | 0.78 | CYP2A6 (0.47) | CYP2A6CYP11B2TRPV1SQORCNR2 | |
| SCHEMBL2140701 | 0.78 | SLC22A12 (0.48) | SLC22A12CYP11B2TDO2TRPV1SQOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040516-B2 | Uracil derivative and use thereof for medical purposes | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-8212048-B2 | Method of producing aromatic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-03 | — | — | US | disclosed |
| CN-101410375-B | Process for producing aromatic compound | SUMITOMO CO LTD | 2012-06-13 | — | — | CN | disclosed |
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| CN-101410375-A | Process for producing aromatic compound | SUMITOMO CHEMICAL CO (JP) | 2009-04-15 | — | — | CN | disclosed |
| US-20090043096-A1 | METHOD OF PRODUCING AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | URB2, ELANE, NUDT1 | CYP2A6 1067/4885SLC22A12 1662/4885CYP11B2 564/4885 |
| US-20090043096-A1 | METHOD OF PRODUCING AROMATIC COMPOUND | AHR, CYP1A1, ARNT | CYP2A6 89/4885SLC22A12 2058/4885CYP11B2 7/4885 |
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | CYP2A6 2573/4885SLC22A12 1217/4885CYP11B2 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.